Zhang Cheng, Zhang Guohai, Ye Zhehao, Hu Guojie, Ge Shengsheng, Luo Kai, Li Zhao
Department of Neurosurgery, Shengzhou Hospital of Traditional Chinese Medicine, Shengzhou, Zhejiang Province, People's Republic of China.
Neuropsychiatr Dis Treat. 2025 Mar 20;21:621-640. doi: 10.2147/NDT.S505346. eCollection 2025.
Peroxiredoxin 2 (Prdx2) functions as an antioxidant and may be involved in acute brain injury. This study aimed to investigate whether Prdx2 can act as a serological marker for assessing the severity and forecasting stroke-associated pneumonia (SAP), early neurological deterioration (END), and neurological outcomes in acute intracerebral hemorrhage (ICH).
A collective of 167 patients with ICH and 61 controls underwent quantifications for serum Prdx2 levels. In addition, 61 of them allowed Prdx2 measurements on days 1, 3, 5, 7, 10, and 14 post-ICH. Admission National Institutes of Health Stroke Scale (NIHSS) score and hematoma size were documented, and the modified Rankin Scale (mRS) at six-month mark following ICH was registered. Correlations between serum Prdx2 and END, SAP, and poor prognosis (mRS scores of 3-6) were determined using multivariate models.
Serum Prdx2 levels of patients rapidly increased after stroke, with the highest levels on day 3, and were substantially higher during the initial 14 days than those of controls. Prdx2 levels were closely related to NIHSS scores, hematoma size, and mRS scores, were linearly relevant to likelihoods of SAP, END, and poor prognosis, and were independently predictive of SAP, END, and poor prognosis. These associations were not markedly affected by age, sex, hypertension, or other factors using subgroup analysis. Moreover, the possibilities of END, SAP, and poor prognosis were efficiently distinguished by Prdx2 levels. Its discrimination efficiency was similar to those of the NIHSS scores and hematoma size. The combination of the three variables displayed a higher predictive ability than the combination of NIHSS scores and hematoma volume for prognosis prediction.
A marked increase in serum Prdx2 levels after ICH may accurately mirror hemorrhagic severity and effectively predict END, SAP, and poor neurological outcomes, solidifying serum Prdx2 as a prognosticator of ICH.
过氧化物酶体增殖物激活受体2(Prdx2)具有抗氧化作用,可能参与急性脑损伤。本研究旨在探讨Prdx2是否可作为评估急性脑出血(ICH)严重程度以及预测卒中相关性肺炎(SAP)、早期神经功能恶化(END)和神经功能结局的血清学标志物。
对167例ICH患者和61例对照者进行血清Prdx2水平定量检测。此外,其中61例患者在ICH后第1、3、5、7、10和14天进行了Prdx2检测。记录入院时的美国国立卫生研究院卒中量表(NIHSS)评分和血肿大小,并记录ICH后6个月时的改良Rankin量表(mRS)评分。使用多变量模型确定血清Prdx2与END、SAP和预后不良(mRS评分为3 - 6)之间的相关性。
卒中后患者血清Prdx2水平迅速升高,在第3天达到最高水平,且在最初14天内显著高于对照组。Prdx2水平与NIHSS评分、血肿大小和mRS评分密切相关,与SAP、END和预后不良的可能性呈线性相关,并且独立预测SAP、END和预后不良。使用亚组分析时,这些关联不受年龄、性别、高血压或其他因素的明显影响。此外,Prdx2水平可有效区分END、SAP和预后不良的可能性。其鉴别效率与NIHSS评分和血肿大小相似。这三个变量的组合在预后预测方面比NIHSS评分和血肿体积的组合具有更高的预测能力。
ICH后血清Prdx2水平显著升高可能准确反映出血严重程度,并有效预测END、SAP和不良神经功能结局,从而确定血清Prdx2为ICH的预后指标。